Table 2.
Characteristics of included HER-2 negative and positive breast cancer patients.
| Variable | HER-2 Negative breast cancer N (%) |
HER-2 positive breast cancer N (%) |
|
|---|---|---|---|
| Age (Mean ± SD) | (51.1 ± 11.2) | (49.9 ± 10.1) | |
| ER status | Positive | 15 (71.4) | 15 (62.5) |
| Negative | 6 (28.6) | 9 (37.5) | |
| PR status | Positive | 15 (71.4) | 12 (50.0) |
| Negative | 6 (28.6) | 12 (50.0) | |
| Tumor size | pT1 | 6 (28.6) | 5 (20.8) |
| pT2 | 13 (61.9) | 14 (58.3) | |
| pT3 | 2 (9.5) | 5 (20.8) | |
| Lymph nodes | N0 | 9 (42.9) | 12 (50.0) |
| N1 | 7 (33.3) | 8 (33.3) | |
| N2 | 3 (14.3) | 4 (16.7) | |
| N3 | 2 (9.5) | 0 (0.0) | |
| Tumor stage | I | 2 (9.5) | 7 (29.2) |
| II | 12 (57.1) | 12 (50.0) | |
| III | 7 (33.3) | 5 (20.8) | |
| Tumor grade | I | 1)4.8) | 3 (12.5) |
| II | 16 (76.2) | 18 (75.0) | |
| III | 4 (19.2) | 3 (12.5) | |
| Histological subtype | IDC | 17 (81.0) | 24 (100.0) |
| ILC | 4 (19.0) | 0 (0.0) | |
| Menopausal status | Premenopausal | 11 (52.4) | 16 (66.6) |
| Postmenopausal | 10 (47.6) | 8 (33.3) |
Abbreviation: ER: esterogene receptor, PR: progesterone receptor.